Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients
Growing evidence suggests that the patient’s immune response may play a major role in the long-term efficacy of antibody therapies of follicular lymphoma (FL). Particular long-lasting recurrence free survivals have been observed after first line, single agent rituximab or after radioimmunotherapy (R...
Saved in:
| Main Authors: | Franz Buchegger, Steven M. Larson, Jean-Pierre Mach, Yves Chalandon, Pierre-Yves Dietrich, Anne Cairoli, John O. Prior, Pedro Romero, Daniel E. Speiser |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2013/875343 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
by: V. I. Chernov, et al.
Published: (2016-07-01) -
BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?
by: Irene Dogliotti, et al.
Published: (2025-07-01) -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
by: Giuseppe Rossi, et al.
Published: (2016-11-01) -
Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections
by: Ekaterina Dadachova, et al.
Published: (2011-01-01) -
Experimental and clinical approaches to a radioimmunotherapy in o
by: E. V. Abakushina, et al.
Published: (2016-02-01)